Natco Pharma Ltd News

Natco Pharma to invest $14 mn in US-based biotechnology firm eGenesis Inc

Natco Pharma on Tuesday said it is investing USD 14 million (over Rs 130 crore) in eGenesis Inc, a US-based biotechnology firm, through its two subsidiaries. As part of the transaction, Natco Pharma (Canada) Inc will invest USD 9.5 million and Natco Pharma South Africa Proprietary Ltd USD 4.5 million in eGenesis through convertible promissory notes, the Hyderabad-based company said in a regulatory filing. eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure, it added. In 2024, Natco Pharma had invested USD 8 million in eGenesis, Inc through preferred stock. The total investment made by it in eGenesis, Inc now stands at USD 22 million, the company said. The eGenesis Genome Engineering and Production (EGEN) platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via ..

Natco Pharma Q1 results: Profit falls 57% to ₹206 cr, revenue at ₹735 cr

Natco Pharma Ltd on Friday reported a 57 per cent decline in consolidated net profit at Rs 206.5 crore in the first quarter ended June 2026, hit by lower sales of its generic cancer treatment drug lenalidomide. The company had posted a consolidated net profit of Rs 480.3 crore in the corresponding quarter last fiscal, Natco Pharma said in a regulatory filing. Consolidated revenue from operations in the first quarter was lower at Rs 735.2 crore in the first quarter as compared to Rs 1,328.9 crore in the corresponding period a year ago, it added. The decline is largely attributable to lower lenalidomide revenue in the current quarter, which was partially offset by growth in the base business, the company said. Total expenses in the quarter under review were lower at Rs 608.8 crore as compared to Rs 818.7 crore in the same period a year ago, it added. In the first quarter, domestic pharmaceutical formulations revenue was at Rs 136.4 crore, up from Rs 107 crore in the year-ago period.

Natco Pharma gains nearly 3% on ₹2,500 crore South Africa investment plan

Natco Pharma has announced investments of nearly ₹2,500 crore in South Africa, including infusing ₹1,400 crore in its arm in the country with an aim to enter new geographies.

Stocks to Watch today: TCS, Tata Steel, GMR Airports, M&M, SBI, HFCL & more

Stocks to watch today: TCS, SBI, Tata Steel, GMR Airports, M&M, HFCL, RIL, Fortis Healthcare, JSW Infra, Swiggy, Pidilite, Shree Cement, among others, will be in focus today

Patent expiry: A $5 bn opportunity for Indian pharma majors, says report

Lupin, Intas Pharmaceuticals, Sun Pharma, MSN Laboratories, Natco Pharma, Zydus Life Sciences and Dr Reddy's Laboratories are some of the companies, the note said, that could potentially benefit.

Natco Pharma stock price slips 20% in 2 days; should you buy, sell or hold?

Natco Pharma's management expects better FY28 with traction coming from Canada, Brazil and India besides some niche launches in the US which can translate into 15- 25 per cent PAT growth.

10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations